Literature DB >> 29509898

TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.

Barbara Ogórek1, Hilaire C Lam1, Damir Khabibullin1, Heng-Jia Liu1, Julie Nijmeh1, Robinson Triboulet2,3, David J Kwiatkowski1, Richard I Gregory2,3, Elizabeth P Henske1.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disease caused by germline inactivating mutations of TSC1 or TSC2. In TSC-associated tumors of the brain, heart, skin, kidney and lung, inactivation of both alleles of TSC1 or TSC2 leads to hyperactivation of the mTORC1 pathway. The TSC/mTORC1 pathway is a key regulator of cellular processes related to growth, proliferation and autophagy. We and others have previously found that mTORC1 regulates microRNA biogenesis, but the mechanisms are not fully understood. Microprocessor, a multi-protein complex including the nuclease Drosha, processes the primary miR transcript. Using a dual-luciferase reporter, we found that inhibition of mTORC1 or downregulation of Raptor decreased Microprocessor activity, while loss of TSC2 led to a striking increase (∼5-fold) in Microprocessor activity. To determine the global impact of TSC2 on microRNAs we quantitatively analyzed 752 microRNAs in Tsc2-expressing and Tsc2-deficient cells. Out of 259 microRNAs expressed in both cell lines, 137 were significantly upregulated and 24 were significantly downregulated in Tsc2-deficient cells, consistent with the increased Microprocessor activity. Microprocessor activity is known to be regulated in part by GSK3β. We found that total GSK3β levels were higher in Tsc2-deficient cells, and the increase in Microprocessor activity associated with Tsc2 loss was reversed by three different GSK3β inhibitors. Furthermore, mTOR inhibition increased the levels of phospho-GSK3β (S9), which negatively affects Microprocessor activity. Taken together these data reveal that TSC2 regulates microRNA biogenesis and Microprocessor activity via GSK3β.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29509898      PMCID: PMC5905583          DOI: 10.1093/hmg/ddy073

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  29 in total

Review 1.  The tuberous sclerosis complex.

Authors:  Peter B Crino; Katherine L Nathanson; Elizabeth Petri Henske
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

2.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.

Authors:  Andrew Y Choo; Sang-Oh Yoon; Sang Gyun Kim; Philippe P Roux; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

3.  An mTORC1-Mdm2-Drosha axis for miRNA biogenesis in response to glucose- and amino acid-deprivation.

Authors:  Peiying Ye; Yu Liu; Chong Chen; Fei Tang; Qi Wu; Xiang Wang; Chang-Gong Liu; Xiuping Liu; Runhua Liu; Yang Liu; Pan Zheng
Journal:  Mol Cell       Date:  2015-01-29       Impact factor: 17.970

4.  Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer.

Authors:  Masaki Mori; Robinson Triboulet; Morvarid Mohseni; Karin Schlegelmilch; Kriti Shrestha; Fernando D Camargo; Richard I Gregory
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

5.  Inducible raptor and rictor knockout mouse embryonic fibroblasts.

Authors:  Nadine Cybulski; Vittoria Zinzalla; Michael N Hall
Journal:  Methods Mol Biol       Date:  2012

6.  Aberrant beta-catenin signaling in tuberous sclerosis.

Authors:  Baldwin C Mak; Heidi L Kenerson; Lauri D Aicher; Elizabeth A Barnes; Raymond S Yeung
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

7.  β-Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis.

Authors:  Richard J Flavin; Jennifer Cook; Michelangelo Fiorentino; Dyane Bailey; Myles Brown; Massimo F Loda
Journal:  Am J Clin Pathol       Date:  2011-05       Impact factor: 2.493

8.  Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.

Authors:  Juxiang Cao; Magdalena E Tyburczy; Joel Moss; Thomas N Darling; Hans R Widlund; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2016-12-05       Impact factor: 14.808

9.  Cytoplasmic Drosha activity generated by alternative splicing.

Authors:  Lisheng Dai; Kevin Chen; Brenda Youngren; Julia Kulina; Acong Yang; Zhengyu Guo; Jin Li; Peng Yu; Shuo Gu
Journal:  Nucleic Acids Res       Date:  2016-07-28       Impact factor: 16.971

10.  Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells.

Authors:  Hilaire C Lam; Heng-Jia Liu; Christian V Baglini; Harilaos Filippakis; Nicola Alesi; Julie Nijmeh; Heng Du; Alicia Llorente Lope; Katherine A Cottrill; Adam Handen; John M Asara; David J Kwiatkowski; Issam Ben-Sahra; William M Oldham; Stephen Y Chan; Elizabeth P Henske
Journal:  Oncotarget       Date:  2017-08-04
View more
  9 in total

1.  Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RARβ).

Authors:  Heng-Jia Liu; Hilaire C Lam; Christian V Baglini; Julie Nijmeh; Alischer A Cottrill; Stephen Y Chan; Elizabeth P Henske
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

2.  Loss of TSC complex enhances gluconeogenesis via upregulation of Dlk1-Dio3 locus miRNAs.

Authors:  Dritan Liko; Andrzej Rzepiela; Vanja Vukojevic; Mihaela Zavolan; Michael N Hall
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-09       Impact factor: 11.205

3.  Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex.

Authors:  Andrii Kovalenko; Andres Sanin; Kosmas Kosmas; Long Zhang; Ji Wang; Elie W Akl; Krinio Giannikou; Clemens K Probst; Thomas R Hougard; Ryan W Rue; Vera P Krymskaya; John M Asara; Hilaire C Lam; David J Kwiatkowski; Elizabeth P Henske; Harilaos Filippakis
Journal:  Cancer Res       Date:  2021-02-16       Impact factor: 13.312

4.  mTORC1 Activation by Loss of Tsc1 in Myelinating Glia Causes Downregulation of Quaking and Neurofascin 155 Leading to Paranodal Domain Disorganization.

Authors:  Qian Shi; Julia Saifetiarova; Anna Marie Taylor; Manzoor A Bhat
Journal:  Front Cell Neurosci       Date:  2018-07-12       Impact factor: 5.505

Review 5.  mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer.

Authors:  Karen Griselda de la Cruz López; Mariel Esperanza Toledo Guzmán; Elizabeth Ortiz Sánchez; Alejandro García Carrancá
Journal:  Front Oncol       Date:  2019-12-13       Impact factor: 6.244

6.  Pyrotinib Targeted EGFR-STAT3/CD24 Loop-Mediated Cell Viability in TSC.

Authors:  Xiao Han; Yupeng Zhang; Yin Li; Zhoujun Lin; Xiaolin Pei; Ya Feng; Juan Yang; Fei Li; Tianjiao Li; Zhenkun Fu; Changjun Wang; Chenggang Li
Journal:  Cells       Date:  2022-09-29       Impact factor: 7.666

7.  miR-9-5p regulates immunometabolic and epigenetic pathways in β-glucan-trained immunity via IDH3α.

Authors:  Haibo Su; Zhongping Liang; ShuFeng Weng; Chaonan Sun; Jiaxin Huang; TianRan Zhang; Xialian Wang; Shanshan Wu; Zhi Zhang; Yiqi Zhang; Qing Gong; Ying Xu
Journal:  JCI Insight       Date:  2021-05-10

Review 8.  Emerging Role of mTOR Signaling-Related miRNAs in Cardiovascular Diseases.

Authors:  Arun Samidurai; Rakesh C Kukreja; Anindita Das
Journal:  Oxid Med Cell Longev       Date:  2018-08-23       Impact factor: 6.543

9.  Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis.

Authors:  Harilaos Filippakis; Amine Belaid; Brian Siroky; Constance Wu; Nicola Alesi; Thomas Hougard; Julie Nijmeh; Hilaire C Lam; Elizabeth P Henske
Journal:  Sci Rep       Date:  2018-09-21       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.